Greenwich LifeSciences, Inc.

NASDAQ:GLSI

13.81 (USD) • At close November 7, 2024
Bedrijfsnaam Greenwich LifeSciences, Inc.
Symbool GLSI
Munteenheid USD
Prijs 13.81
Beurswaarde 181,528,307
Dividendpercentage 0%
52-weken bereik 8 - 21.44
Industrie Biotechnology
Sector Healthcare
CEO Mr. Snehal S. Patel
Website https://greenwichlifesciences.com

An error occurred while fetching data.

Over Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone

Vergelijkbare Aandelen

Rezolute, Inc. logo

Rezolute, Inc.

RZLT

5.72 USD

Selecta Biosciences, Inc. logo

Selecta Biosciences, Inc.

SELB

0.881 USD

FONAR Corporation logo

FONAR Corporation

FONR

15.13 USD

CytomX Therapeutics, Inc. logo

CytomX Therapeutics, Inc.

CTMX

1 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)